α‑spinasterol from Melandrium firmum attenuates benign prostatic hyperplasia in a rat model

Lee,Mee‑Young; Shin,In‑Sik; Kyoung,Hwangbo; Seo,Chang‑Seob; Son,Jong-Keun; Shin,Hyeun‑Kyoo

doi:10.3892/mmr.2014.2081

α‑spinasterol from Melandrium firmum attenuates benign prostatic hyperplasia in a rat model

Authors:
- Mee‑Young Lee
- In‑Sik Shin
- Hwangbo Kyoung
- Chang‑Seob Seo
- Jong-Keun Son
- Hyeun‑Kyoo Shin
View Affiliations

Affiliations: Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine, Yuseung‑gu, Daejeon 305‑811, Republic of Korea, College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongsangbuk-do 712‑749, Republic of Korea
Published online on: March 28, 2014 https://doi.org/10.3892/mmr.2014.2081
Pages: 2362-2366

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Spinasterol, a biologically active compound, exhibits a number of pharmacological activities, including antitumor, antiulcerogenic and anticarcinogenic activity, and originates from the aerial parts of Aster scaber Thunb (Asteraceae). The present study investigated whether α‑spinasterol isolated from Melandrium firmum Rohrbach could prevent benign prostatic hyperplasia (BPH) induced by testosterone propionate (TP) in rats. Male Wistar rats were randomly divided into four groups of eight rats following castration. A negative control group received subcutaneous injections of corn oil. Treatments were administered orally 1 h prior to TP injection. All the rats were sacrificed at the scheduled termination time and their prostates were removed, cleaned and weighed. The prostate size ratio (prostate weight/rat body weight) was then calculated. Additional histopathological examinations were conducted, and the levels of TP and dihydrotestosterone (DHT) in the serum and prostate were measured. TP significantly increased the prostate size ratio (P<0.01), and DHT and testosterone levels in the serum and prostate. The TP‑induced increase was significantly inhibited in α‑spinasterol‑treated rats when compared with the negative controls (P<0.05). In addition, histopathological examination demonstrated that α‑spinasterol treatment suppressed TP‑induced prostatic hyperplasia. It is concluded that α‑spinasterol can prevent TP‑induced prostatic hyperplasia and may be beneficial in the management of BPH.

View Figures

View References

1	Parsons JK and Kashefi C: Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. EurUrol. 53:1228–1235. 2008.PubMed/NCBI
2	Roehrborn CG, Siami P, Barkin J, Damião R, Gecher E, Miñana B, Mirone V, Castro R, Wilson T and Montorsi F: The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol. 55:461–471. 2009.
3	McConnell JD: Benign prostatic hyperplasia. Hormonal treatment Urol Clin North Am. 22:387–400. 1995.
4	Wemyss-Holden SA, Hamdy FC and Hastie KJ: Steroid abuse in athletes, prostatic enlargement and bladder outflow obstruction - is there a relationship? Br J Urol. 74:476–478. 1994. View Article : Google Scholar : PubMed/NCBI
5	Bruchovsky N, Rennie PS, Batzold FH, Goldenberg SL, Fletcher T and McLoughlin MG: Parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. J Clin Endocrinol Metab. 67:806–816. 1998. View Article : Google Scholar : PubMed/NCBI
6	Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD and Russell DW: Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 92:903–910. 1993. View Article : Google Scholar : PubMed/NCBI
7	Carson C III and Rittmaster R: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 61(4 Suppl 1): 2–7. 2003. View Article : Google Scholar : PubMed/NCBI
8	Kumar VL and Wahane VD: Current status of 5α-reductase inhibitors in the treatment of benign hyperplasia of prostate. Indian J Med Sci. 62:167–175. 2008.
9	De Nunzio C, Miano R, Trucchi A, Finazzi Agrò E and Tubaro A: Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin Drug Metab Toxicol. 4:1561–1568. 2008.PubMed/NCBI
10	Steers WD: 5alpha-reductase activity in the prostate. Urology. 58(6 Suppl 1): 17–24. 2001. View Article : Google Scholar : PubMed/NCBI
11	Guess HA, Heyse JF and Gormley GJ: The effect of finasteride on prostatic-specific antigen in men with benign prostatic hyperplasia. Prostate. 22:31–37. 1993. View Article : Google Scholar : PubMed/NCBI
12	Bullock TL and Andriole GL Jr: Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs. 11:111–123. 2006. View Article : Google Scholar : PubMed/NCBI
13	Jeon GC, Park MS, Yoon DY, Shin CH, Sin HS and Um SJ: Antitumor activity of spinasterol isolated from Pueraria roots. Exp Mol Med. 37:111–120. 2005. View Article : Google Scholar : PubMed/NCBI
14	Klein LC Jr, Gandolfi RB, Santin JR, Lemos M, CechinelFilho V and de Andrade SF: Antiulcerogenic activity of extract, fractions, and some compounds obtained from Polygala cyparissias St Hillaire & Moquin (Polygalaceae). Naunyn-Schmiedebergs Arch Pharmacol. 381:121–126. 2010. View Article : Google Scholar : PubMed/NCBI
15	Villaseñor IM and Domingo AP: Anticarcinogenicity potential of spinasterol isolated from squash flowers. Teratog Carcinog Mutagen. 20:99–105. 2000.PubMed/NCBI
16	Zhou CC, Sun XB, Liu JY, Luo SQ and Lu CY: Anti-inflammatory effect of alpha-spinasterol. Acta Pharmaceutica Sinica. 20:257–261. 1985.(In Chinese).
17	Maggi CA, Manzini S, Giuliani S and Meli A: Infravesical outflow obstruction in rats: A comparison of two models. Gen Pharmacol. 20:345–349. 1989. View Article : Google Scholar : PubMed/NCBI
18	Scolnik MD, Servadio C and Abramovici A: Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J Androl. 15:287–297. 1994.PubMed/NCBI
19	Van Coppenolle F, Le Bourhis X, Carpentier F, Delaby G, Cousse H, Raynaud JP, Dupouy JP and Prevarskaya N: Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comprison with finasteride. Prostate. 43:49–58. 2000.
20	VeereshBabu SV, Veeresh B, Patil AA and Warke YB: Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol. 626:262–265. 2010. View Article : Google Scholar : PubMed/NCBI
21	Miller J and Tarter TH: Combination therapy with dutasteride and tamulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging. 4:251–258. 2009.PubMed/NCBI
22	Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D and Tindall D: Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 172:1399–1403. 2004. View Article : Google Scholar : PubMed/NCBI